Aging
involves
seemingly
paradoxical
changes
in
energy
metabolism.
Molecular
damage
accumulation
increases
cellular
expenditure,
yet
whole-body
expenditure
is
stable
or
decreases
with
age.
We
resolve
this
apparent
contradiction
by
positioning
the
brain
as
mediator
and
broker
economy
of
within
organism.
As
somatic
tissues
accumulate
over
time,
costly
intracellular
stress
responses
are
activated,
causing
aging/senescent
cells
to
secrete
cytokines
that
convey
increased
demand
(hypermetabolism)
brain.
To
conserve
face
a
shrinking
budget,
deploys
conservation
responses,
which
suppress
low
priority
processes,
producing
fatigue,
physical
inactivity,
blunted
sensory
capacities,
immune
alterations,
endocrine
“deficits”.
term
cascade
Brain-body
Energy
Conservation
(BEC)
model
aging.
The
BEC
outlines
i)
energetic
cost
aging,
ii)
how
perception
senescence-associated
hypermetabolism
may
drive
manifestations
iii)
principles
underlying
modifiability
aging
trajectories
stressors
geroscience
interventions.
Mechanisms of Ageing and Development,
Год журнала:
2024,
Номер
222, С. 111995 - 111995
Опубликована: Окт. 9, 2024
Fisetin,
a
flavonoid
naturally
occurring
in
plants,
fruits,
and
vegetables,
has
recently
gained
attention
for
its
potential
role
as
senotherapeutic
agent
the
treatment
of
age-related
chronic
diseases.
Senotherapeutics
target
senescent
cells,
which
accumulate
with
age
disease,
both
circulating
immune
cell
populations
solid
organs
tissues.
Senescent
cells
contribute
to
development
many
diseases,
primarily
by
eliciting
systemic
inflammation
through
their
senescence-associated
secretory
phenotype.
Here,
we
explore
whether
fisetin
can
eliminate
thereby
alleviate
examining
current
evidence
from
vitro
studies
animal
models
that
investigate
fisetin's
impact
on
well
phase
I/II
trials
various
patient
populations.
We
discuss
application
humans,
including
challenges
future
directions.
Our
review
available
data
suggests
targeting
offers
promising
strategy
managing
multiple
potentially
transforming
healthcare
older
multimorbid
patients.
However,
further
are
needed
establish
safety,
pharmacokinetics,
efficacy
senotherapeutic,
identify
relevant
reliable
outcome
measures
human
trials,
optimize
dosing,
better
understand
possible
limitations
agent.
Mediators of Inflammation,
Год журнала:
2025,
Номер
2025(1)
Опубликована: Янв. 1, 2025
Background:
Osteosarcopenia,
the
coexistence
of
osteoporosis
and
sarcopenia,
poses
significant
challenges
in
aging
populations
due
to
its
dual
impact
on
bone
muscle
health.
Inflammation,
mediated
by
specific
cytokines,
is
thought
play
a
crucial
role
development
osteosarcopenia,
though
underlying
mechanisms
are
not
fully
understood.
Objective:
This
study
aimed
clarify
causal
circulating
cytokines
pathogenesis
osteosarcopenia
employing
mendelian
randomization
(MR)
single-cell
RNA
sequencing
(scRNA-seq)
identify
cell-specific
cytokine
expression
patterns.
The
ultimate
objective
was
uncover
potential
pathological
therapeutic
targets
for
treating
osteosarcopenia.
Methods:
A
two-sample
MR
approach
employed,
leveraging
publicly
available
genome-wide
association
(GWAS)
data
from
multiple
cohorts.
total
91
were
examined
using
genetic
instruments,
their
effects
traits
related
sarcopenia
evaluated.
Various
complementary
sensitivity
analyses
performed
ensure
robust
findings.
Additionally,
scRNA-seq
datasets
human
marrow
analyzed
validate
profiles
candidate
cytokines.
Results:
analysis
identified
several
with
traits,
including
LTA,
CD40,
CXCL6,
CXCL10,
DNER
(delta
notch-like
epidermal
growth
factor-related
receptor),
VEGFA
(vascular
endothelial
factor
A).
LTA
CD40
protective
both
muscle,
while
posed
risk.
Other
demonstrated
opposite
muscle.
Single
cell
revealed
distinct
patterns,
highly
expressed
lymphocytes,
immune
cells,
various
musculoskeletal
types.
Age-related
differences
also
noted,
more
younger
individuals,
older
individuals.
Conclusion:
offers
preliminary
insights
into
inflammatory
potentially
driving
identifying
key
that
may
be
involved
pathogenesis.
By
integrating
data,
we
highlight
targets,
further
research
needed
confirm
these
findings
implications
Frontiers in Cardiovascular Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Апрель 8, 2025
Advanced
glycation
end-products
(AGEs)
may
contribute
to
the
pathogenesis
of
atherosclerotic
cardiovascular
disease
(ASCVD),
potentially
influencing
its
development
and
progression
differently
at
various
life
stages.
This
study
aimed
elucidate
associations
between
AGEs
risk
ASCVD
across
different
age
groups.
In
this
cross-sectional
study,
1,240
subjects
were
enrolled
divided
into
three
groups
(Group
Ⅰ,
20-39
years
old,
n
=
468;
Group
Ⅱ,
40-59
471;
Ⅲ,
60-79
301).
Skin
measured
by
skin
autofluorescence
(SAF).
was
assessed
a
validated
Framingham
score
calculator.
Other
proven
factors
also
measured,
including
glycosylated
hemoglobin,
uric
acid,
lipid
profile,
homocysteine,
cystatin
C.
An
increasing
trend
in
observed
from
Ⅰ
Ⅲ.
significantly
associated
with
all
(OR
1.029,
95%
CI
1.003-1.056,
P
0.018),
independent
some
factors.
association
particularly
significant
individuals
aged
1.047,
CI:
1.025-1.069;
OR
1.022,
1.002-1.042;
both
<
0.05).
ROC
analysis
showed
that
predicted
diagnosis
medium
or
high
pooled
group,
Our
substantiates
play
an
important
role
as
factor
for
ASCVD,
highlighting
their
significance
beyond
traditional
assessment
models,
middle-aged
older
populations.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(12), С. 6793 - 6793
Опубликована: Июнь 20, 2024
Aging
is
a
complex
and
time-dependent
decline
in
physiological
function
that
affects
most
organisms,
leading
to
increased
risk
of
age-related
diseases.
Investigating
the
molecular
underpinnings
aging
crucial
identify
geroprotectors,
precisely
quantify
biological
age,
propose
healthy
longevity
approaches.
This
review
explores
pathways
are
currently
being
investigated
as
intervention
targets
biomarkers
spanning
molecular,
cellular,
systemic
dimensions.
Interventions
target
these
hallmarks
may
ameliorate
process,
with
some
progressing
clinical
trials.
Biomarkers
used
estimate
aging-associated
disease.
Utilizing
biomarkers,
clocks
can
be
constructed
predict
state
abnormal
aging,
diseases,
mortality.
Biological
age
estimation
therefore
provide
basis
for
fine-grained
stratification
by
predicting
all-cause
mortality
well
ahead
onset
specific
thus
offering
window
intervention.
Yet,
despite
technological
advancements,
challenges
persist
due
individual
variability
dynamic
nature
biomarkers.
Addressing
this
requires
longitudinal
studies
robust
biomarker
identification.
Overall,
utilizing
discover
new
drug
develop
opens
frontiers
medicine.
Prospects
involve
multi-omics
integration,
machine
learning,
personalized
approaches
targeted
interventions,
promising
healthier
population.
Abstract
Patients
with
chronic
kidney
disease
(CKD)
have
increased
oxidative
stress
and
inflammation,
which
may
escalate
the
production
of
advanced
glycation
end‐products
(AGEs).
High
soluble
receptor
for
AGE
(sRAGE)
low
estimated
glomerular
filtration
rate
(eGFR)
levels
are
associated
CKD
aging.
We
evaluated
whether
eGFR
calculated
from
creatinine
cystatin
C
share
pleiotropic
genetic
factors
sRAGE.
employed
whole‐genome
sequencing
correlated
meta‐analyses
on
combined
genome‐wide
association
study
(GWAS)
p
‐values
in
4182
individuals
(age
range:
24–110)
Long
Life
Family
Study
(LLFS).
also
conducted
transcriptome‐wide
studies
(TWAS)
whole
blood
a
subset
1209
individuals.
identified
59
GWAS
loci
(
<
5
×
10
−8
)
17
TWAS
genes
(Bonferroni‐
2.73
−6
traits
genes,
LSP1
MIR23AHG
,
were
sRAGE
located
within
loci,
lncRNA‐
KCNQ1OT1
CACNA1A/CCDC130
respectively.
variants
eQTLs
glomeruli
tubules,
predicted
carcinoma.
harbored
kidney,
carcinoma,
connected
enhancer‐promoter
function‐related
phenotypes
at
.
Additionally,
higher
allele
frequencies
protective
detected
LLFS
than
ALFA‐Europeans
TOPMed,
suggesting
better
function
healthy‐aging
general
populations.
Integrating
genomic
annotation
transcriptional
gene
activity
revealed
enrichment
elements
aging‐
related
processes.
The
expressions
suggest
their
underlying
shared
effects
highlight
roles
kidney‐
aging‐related
signaling
pathways.
Aging
has
profound
effects
on
the
body,
most
notably
an
increase
in
prevalence
of
several
diseases.
An
important
aging
hallmark
is
presence
senescent
cells
that
no
longer
multiply
nor
die
off
properly.
Another
characteristic
altered
immune
system
fails
to
properly
self-surveil.
In
this
multi-player
process,
cellular
senescence
induces
a
change
secretory
phenotype,
known
as
senescence-associated
phenotype
(SASP),
many
with
intention
recruiting
accelerate
clearance
these
damaged
cells.
However,
SASP
results
inducing
secondary
nearby
cells,
resulting
those
becoming
senescent,
and
improper
activation
state
chronic
inflammation,
called
inflammaging,
Senescence
termed
immunosenescence,
further
dysregulation
system.
interdisciplinary
approach
needed
physiologically
assess
changes
at
tissue
level.
Thus,
intersection
biomaterials,
microfluidics,
spatial
omics
great
potential
collectively
model
immunosenescence.
Each
approaches
mimics
unique
aspects
body
undergoes
part
aging.
This
perspective
highlights
key
how
biomaterials
provide
non-cellular
cues
cell
aging,
microfluidics
recapitulate
flow-induced
multi-cellular
dynamics,
analyses
dissect
coordination
biomarkers
function
interactions
distinct
environments.
overview
play
role
organ
cancer,
wound
healing,
Alzheimer's,
osteoporosis
included.
To
illuminate
societal
impact
increasing
trend
anti-senescence
anti-aging
interventions,
including
pharmacological
medical
procedures,
lifestyle
discussed,
context
senescence.
Greater
insights
into
biological
mechanisms
(hallmarks)
of
aging,
their
associations
with
aging-related
diseases
and
disabilities,
early
evidence
that
they
can
be
modified
by
intervention
have
generated
intense
interest
in
testing
the
geroscience
hypothesis;
is,
interventions
targeting
hallmarks
aging
will
delay
or
even
prevent
age-related
disabilities.
This
innovative
potentially
disruptive
approach
to
optimize
human
health
has
revealed
need,
potential,
challenges
for
operationalizing
markers,
biomarkers,
aging.
Sensitive
specific
methods
continue
progress
quantifying
loss
proteostasis,
mitochondrial
dysfunction,
epigenetic
alterations,
oxidative
damage,
cellular
senescence,
other
(Lopez-Otin
et
al.,
2023)
at
tissue
single
cell
levels,
particularly
preclinical
models.
Their
utility
humans,
however,
limited
accessibility
tissues
most
vulnerable
conditions,
example,
heart,
brain,
lung,
kidney.
challenge
driven
National
Institute
on
Aging
(https://predictivebiomarkers.org/),
a
recently
formed
Biomarkers
Consortium
(https://www.agingconsortium.org/),
entities
develop
feasible,
valid,
and,
context
hallmarks,
modifiable
biomarkers
(Moqri
2023,
2024;
Rutledge
2022).
As
an
we
exploited
literature
secretome
several
types
induced
senescence
vitro
candidate
panel
comprised
cytokines,
chemokines,
matrix
remodeling
proteins,
growth
factors,
could
reliably
measured
blood
humans
(Schafer
2020).
We
observed
expected
changes
circulating
abundance
conditions
associated
increased
senescent
burden,
including
advanced
chronological
age,
frailty,
disability,
chronic
disease
(Aversa,
Atkinson,
2023;
Fielding
Schafer
Most
recently,
studied
biospecimens
clinical
data
from
Comprehensive
Assessment
Long-term
Effects
Reducing
Intake
Energy
(CALERIE™)
study
demonstrated
participants
randomized
2
years
calorie
restriction
had
reduced
concentrations
Year
1
compared
those
ad
libitum
diet
White,
2023).
In
thoughtful
categorization
as
response,
predictive,
surrogate,
proposed
Cummings
Kritchevsky,
change
senescence-related
proteins
response
would
support
use
(Cummings
&
Response
are
critical
advancement
pharmacological
part,
such
provide
confirmation
early-phase
trials
target
engagement
(e.g.,
reduction
burden
secretory
phenotype
cells
reprogramming
epigenome
more
youthful
state)
guide
optimal
dose
dosing
regimens.
If
field
is
so
fortunate
arsenal
distinct,
albeit
interrelated,
these
may
also
foster
personalized
medicine
selection
right
intervention,
person,
time.
However,
hurdles
track
translation
persist.
For
whether
reflect
average
state
across
all
organs
strongly
influenced
age
particular
organ
unclear.
Similarly,
accessible
informative
lungs
pulmonary
disease)
remains
demonstrated.
A
recent
showing
sets
linked
highlights
potential
overcome
barriers
our
reflective
given
(Oh
Another
key
question
activity
hallmark
predictive
longer
term
outcomes
regulatory
agencies,
how
one
feels,
functions,
survives.
reasonable
application
but,
this
stage,
largely
unanswered.
than
1900
relatively
healthy
older
adults
either
zero
condition
baseline,
was
able
predict
mortality
better
combination
sex,
race,
presence
(St
Sauver
Moreover,
CALERIE™
participants,
reported
were
highly
homeostatic
model
insulin
resistance
calculation
sensitivity
suggest
serve
perhaps
surrogate
which
respond
future
outcomes.
classic
example
biomarker
pressure.
restriction,
like
exercise,
undoubtedly
mediates
improvements
metabolic
through
multiple
mechanisms,
limiting
causal
attribution
(i.e.,
elimination
suppression
responsible
benefits
restriction).
Additional
research
needed
determine
specifically
cells,
genomic
instability,
deregulated
nutrient-sensing,
stem
exhaustion,
etc.,
recognized
metabolic,
musculoskeletal,
cardiovascular,
immunological,
cognitive
function,
line
hypothesis.
Finally,
it
should
noted
offer
decision
making,
absence
hallmarks.
Individuals
presumably
heightened
vulnerability
disabilities
poor
medical
surgical
drug
toxicity,
complications,
length
hospital
stay,
rehospitalization).
Indeed,
DNA
methylation,
somatic
mutations,
shown
predicting
risk
adverse
events
(Fielding
Jaiswal
Ebert,
2019;
Mahapatra
McCrory
2021).
It
plausible
used
existing
calculators,
now
heavily
inform
decisions,
electing
conservative
versus
aggressive
management
condition,
prescribing
prehabilitation
prior
proactively
initiating
comprehensive
transitional
care
plans
rehospitalization
following
discharge
hospital.
Given
promise,
exciting
observe
contribute
current
multidisciplinary
collaborative
efforts
within
test
The
expectation
help
advance
hypothesis
compelling
premise
practice.
NKL
grateful
helpful
discussions
feedback
colleagues
Robert
Arlene
Kogod
Center
Mayo
Clinic
Dr.
Steve
University
California
San
Francisco
Pacific
Medical
Center.
supported
grants
(AG062413,
AG055529,
AG079754,
AG058738,
AG044170)
Glenn
Foundation
Research.
intellectual
property
related
work
licensed
commercial
entity.
been
reviewed
Conflict
Interest
Review
Board
being
conducted
compliance
Clinic's
policies.